Colorectal cancer (CRC) is still an important threat to global health, and thus, is the goal of numerous subsequent research attempts that lead towards more effective therapies. Over the past few decades, different molecular subtypes of colorectal cancer (CRC) have emerged as major areas of interest. The geographical distribution and key drugs that were being tested in these new categories are among those described by recent analysis and ClinicalTrials.gov data. In turn, this analysis served as a snapshot of the breadth and depth with which research is focused today by showing us some of the current headliners in colorectal cancer therapy.
We have analyzed that the United States presents the greatest number of clinical trials concerning colorectal cancer. This can be accounted for by the country’s prestige and technological advancement as well as investments in cancer research. However, clinical trials in countries such as Germany and France or in China also present a focus on extensive cancer research. This shows how the issue of colorectal cancer is global and the strategic and geographical diversities on each continent of conducting trials to fight the disease.
Current and promising drugs under scrutiny in colorectal cancer include the use of immunotherapy, of drugs like Pembrolizumab and Nivolumab – these are immune checkpoint inhibitors. Although used and considered for a variety of cancers, they have begun to be used in increasing concentration for the aid of colorectal cancer. Targeted therapy is another drug focus. Examples are Cetuximab, an antibody-drug used to inhibit pieces of the EGFR receptor, and Bevacizumab – which blocks the effects of angiogenesis and is trialed for different stages of cancer – colorectal being one.
|
Mechanism of Action |
Key Drugs |
Number of Trials |
|---|---|---|
|
Immune Checkpoint Inhibition |
Pembrolizumab, Nivolumab, Atezolizumab |
250 |
|
EGFR Inhibition |
Cetuximab, Panitumumab |
180 |
|
Angiogenesis Inhibition |
Bevacizumab, Aflibercept |
170 |
|
Tyrosine Kinase Inhibition |
Regorafenib, Lenvatinib |
90 |
|
BRAF Inhibition |
Encorafenib (often used in combination with Cetuximab) |
60 |
|
Microsatellite Instability-High (MSI-H) Tumors |
Pembrolizumab, Nivolumab |
120 |
|
Mismatch Repair Deficiency (dMMR) Tumors |
Pembrolizumab, Nivolumab |
110 |
Most of the clinical trials concentrate on advanced or metastatic colorectal cancer, which is difficult to treat. Special importance is placed on microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) tumors, which have a high response rate with immunotherapy. Rapidly growing lines of research are also honing in on BRAF-mutant and KRAS-mutant subtypes, known to be associated with worse prognosis but few or less effective treatment options. Specifically, personalized medicine has become the dominant trend in cancer therapies including lung adenocarcinoma, so targeting to a defined genetic subtypes is essential.
The trials and tribulations in colorectal cancer are leading to a new generation of treatments. A heavy emphasis on immunotherapy and targeted therapeutics may well drive further developments in the way that these precision approaches are used for difficult-to-treat or advanced CRC phenotypes, boding a better future for some of those patients. These figures reveal aspects of the worldwide reach and a potential requirement for more international cooperation to expedite adjuvant therapy development.
These trials will not only drive the behaviour of modern clinicians, but also have far-reaching regulatory and market implications as new data from them change the way we understand medicine. For this reason, it is essential for pharmaceutical companies and healthcare providers to be up-to-date with these emerging trends in order to adapt their approaches accordingly, allowing them to stay competitive within the changing colorectal cancer treatment landscape.
Table of Contents
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3.1 Top-Down Approach
3.2 Bottom-Up Approach
3.3 Data Validation
3.4 Primary Interviews
4.1 Overview of Ongoing Clinical Trials
4.2 Geographical Distribution of Research Efforts
5.1 Detailed Country-wise Breakdown of Ongoing Trials
5.2 Comparative Analysis and Global Hotspots for Colorectal Cancer Research
6.1 Profiles of Top Drugs in Current Clinical Trials
6.2 Analysis of Drug Efficacy and Safety Based on Current Data
7.1 Detailed Analysis of Trials Focusing on MSI-H and dMMR Tumors
7.2 Trends and Outcomes in Targeting Specific Subtypes
8.1 Phase-wise Distribution of Ongoing Trials
8.2 Insights into Progression and Focus of Research Across Different Phases
9.1 Overview of Global Regulatory Frameworks Affecting Clinical Trials
9.2 Impact of Regulations on Trial Designs and Market Entry
10.1 Market Size and Forecast (2022-2032)
10.2 Impact of Clinical Trial Outcomes on Market Dynamics
11.1 Predictive Analysis Based on Current Trials and Historical Data
11.2 Potential Future Trends and Breakthroughs in Treatment
12.1 Insights for Stakeholders in the Pharmaceutical and Healthcare Sectors
12.2 Recommendations Based on Current Trends and Market Needs
13.1 Glossary of Terms
13.2 List of Abbreviations
13.3 References and Data Sources
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
